BioTuesdays

Tag - CHEK

Check Cap
Developments

Check-Cap reviewing strategic alternatives

Check-Cap (NASDAQ:CHEK) is exploring strategic alternatives, such as the sale of all or part of the company, licensing, merger or reverse merger, and has retained Ladenburg Thalmann as an advisor to the company. Check...

June 6, 2023
Check Cap
Markets

Dawson James ups Check-Cap to buy; PT $1

Dawson James Securities upgraded Check-Cap (NASDAQ:CHEK) to “buy” from “neutral” and maintained its price target of $1. The stock closed at 60 cents on Feb. 4. The company’s C-Scan is a colorectal cancer screening test...

February 7, 2022
Check Cap
Markets

Dawson James starts Check Cap at buy; PT $4

Dawson James Securities initiated coverage of Check Cap (NASDAQ:CHEK) with a “buy” rating and $4 price target. The stock closed at $1.39 on Dec. 4. The company has developed an imaging technology’ known as C-Scan, using...

December 5, 2019